Spots Global Cancer Trial Database for Pre-approval Single-patient Expanded Access for Elranatamab (PF-06863135)
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Pre-approval Single-patient Expanded Access for Elranatamab (PF-06863135)
Official Title:
Study ID: NCT05238311
Conditions
Interventions
Study Description
Brief Summary: Provide pre-approval single-patient Expanded Access (Compassionate Use) of elranatamab for patients with relapsed/refractory multiple myeloma
Detailed Description: In Expanded Access, treating physicians are the Sponsors Expanded Access requests from treating physicians should be directed to www.pfizercares.com Availability will depend on location.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
